Artificial Tears Study in Mild to Moderate Dry Eye Patients - Full Text View

Sponsored by:	Advanced Medical Optics
Information provided by:	Advanced Medical Optics
ClinicalTrials.gov Identifier:	NCT00607776

Purpose

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Condition	Intervention	Phase
Dry Eye	Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 Drug: Systane	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Official Title:	Artificial Tears Study in Mild to Moderate Dry Eye Patients

Further study details as provided by Advanced Medical Optics:

Primary Outcome Measures:

Subjective ocular comfort [ Time Frame: 1 Month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Arms	Assigned Interventions
1: Active Comparator Systane	Drug: Systane Drops
2: Experimental Blink tears	Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 Drops

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00607776

Sponsors and Collaborators

Advanced Medical Optics

Investigators

Principal Investigator:

Eric Donnenfeld, M.D.

Ophthalmic Consultants of Long Island

More Information

Responsible Party:	AMO, Inc. ( Lynn Lasswell, O.D., Director, Eye Care Clinical Research )
Study ID Numbers:	PEGT-104-9582
Study First Received:	December 19, 2007
Last Updated:	February 5, 2008
ClinicalTrials.gov Identifier:	NCT00607776
Health Authority:	United States: Institutional Review Board

Keywords provided by Advanced Medical Optics:

dry, eyes
Amelioration of dry eye symptoms

Study placed in the following topic categories:

Lacerations

ClinicalTrials.gov processed this record on January 16, 2009